Drug Profile
Research programme: human monoclonal antibodies - Amgen/Pfizer
Latest Information Update: 13 Mar 2008
Price :
$50
*
At a glance
- Originator Amgen; Pfizer
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Cardiovascular disorders; Inflammation
Most Recent Events
- 03 Apr 2006 Abgenix has been acquired and merged into Amgen
- 04 Feb 2004 Pfizer has filed an IND with the FDA in the US for an undisclosed indication
- 18 Jul 2003 Pfizer has filed an IND with the FDA in the US for an undisclosed indication